Results 241 to 250 of about 1,979,534 (305)

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model‐based simulation of the positioning imatinib for pulmonary arterial hypertension trial

British Journal of Clinical Pharmacology, EarlyView.
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said, Robert B. de Mooij, Dian Jiao, Reitze J. Ovelgonne, Rami Biram, Juan Delgado‐SanMartin, Alexander M. K. Rothman, Sofia S. Villar, Andreas A. Roussakis, Jurjan Aman, Ron A. A. Mathôt, Eleonora L. Swart, Martin R. Wilkins, Imke H. Bartelink   +13 more
wiley   +1 more source

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases. [PDF]

Drugs
Giri BR, Spahn JE, Alsaidalani R, Behrend-Keim B, Bhia M, Doyle JH, Herpin MJ, Moore RC, Murali NS, Safak A, Smyth HDC.   +10 more
europepmc   +1 more source

Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Alpha‐1‐antitrypsin (A1AT) is a multifunctional, clinically important, high‐value therapeutic glycoprotein that can be used for the treatment of many diseases, such as A1AT deficiency, diabetes, graft‐versus‐host disease, cystic fibrosis, and various viral infections. Currently, the only U.S. food and drug administration‐approved treatment for
Frances Rocamora, Chen‐Lin Hsieh, Sanne Schoffelen, Johnny Arnsdorf, Eric A. Toth, Abdul S. Yunus, Thomas E. Cleveland IV, Sara Petersen Bjørn, Mina Ying Min Wu, Noel G. McElvaney, Bjørn Gunnar Rude Voldborg, Thomas R. Fuerst, Nathan E. Lewis   +12 more
wiley   +1 more source

Preliminary pharmacokinetic investigations of hydroxylated metabolites after controlled inhalative and oral consumption of hexahydrocannabinol (HHC). [PDF]

Sci Rep
Höfert L, Schirmer W, Mösch I, Franz B, Groß C, Becker S, Baumann S.   +6 more
europepmc   +1 more source

Compliant hydrogel cuff coating with real‐time pressure monitoring and antibiofilm capabilities for ventilator‐associated pneumonia prophylaxis

BMEMat, EarlyView.
A soft‐compliant hydrogel cuff coating combines real‐time pressure monitoring with intrinsic antibacterial activity for prophylaxis of ventilator‐associated pneumonia. A flexible pressure‐sensing patch is embedded in the coating to enable wireless dynamic monitoring of endotracheal cuff pressure through Bluetooth.
Jin Chai, Yifu Tan, Jiaheng Liang, Shen Liu, Jiabin Zhao, Shanbo Ma, Chunxin Liu, Minghua Du, Mark Selvan, Xiaopeng Shi, Liqiang Song, Peng Li   +11 more
wiley   +1 more source

Inhaled sphingosine reduces bronchial Pseudomonas aeruginosa burden during porcine ex vivo lung perfusion and shows tissue delivery in explanted human lungs. [PDF]

Sci Rep
Liu Y, Schumacher F, Wu Y, Leukers L, Schimank K, Abou-Issa O, Taube C, Wissmann A, Pizanis N, Kleuser B, Koch A, Gulbins E, Kamler M.   +12 more
europepmc   +1 more source

2,2'-Dichlorodiethyl ether: MAK Value Documentation, addendum - Translation of the German version from 2023. [PDF]

MAK Collect Occup Health Saf
Hartwig A, MAK Commission.
europepmc   +1 more source

Salivary responses to chewing mastic resin and parafilm and inhalation of mastic- and α-pinene-derived volatiles in healthy young adults. [PDF]

Front Dent Med
Assy Z, Potocka W, Albogatjiew C, Özcan A, Bikker FJ, Laine ML.   +5 more
europepmc   +1 more source

Nebulised Chinese herbal medicine for paediatric pneumonia: a meta-analysis. [PDF]

Front Pediatr
Shen J, Li Y, Wei M, Qin T.
europepmc   +1 more source

Delivering the blueprint: Advances and challenges in mRNA therapeutics for the respiratory system. [PDF]

Int J Pharm X
Jia F, Ma L, Li Y.
europepmc   +1 more source